Sobetirome (NV1205) ( DrugBank: Sobetirome )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
20副腎白質ジストロフィー1

20. 副腎白質ジストロフィー


臨床試験数 : 61 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03196765
(ClinicalTrials.gov)
August 20185/5/2017Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With AdrenoleukodystrophyPhase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)X-Linked AdrenoleukodystrophyDrug: Sobetirome (NV1205)NeuroVia, Inc.NULLWithdrawn4 Years18 YearsMale0Phase 1/Phase 2Argentina;Australia;Chile;Colombia;France;Russian Federation;Ukraine;United Kingdom